Highlights

  • 1

    Novel treatment strategies in immunotherapy for breast cancer

  • 2

    Approval of Atezolizumab, a PD-L1 inhibitor

  • 3

    Women with locally advanced or metastatic triple-negative breast cancer

  • 4

    Biomarkers identification and patients benefit

Summary

Novel treatment strategies in immunotherapy are benefiting breast cancer patients. Atezolizumab, a PD-L1 inhibitor, has been approved by the FDA, in combination with the chemotherapy drug nab-paclitaxel, for the initial treatment of women with locally advanced or metastatic triple-negative breast cancer that cannot be treated surgically and whose tumors are positive for PD-L1 protein. What biomarkers have been identified? How can they benefit patients?

This event is sponsored by: :

Interviewee

User

Sherene Loi MD, PhD

Group Leader, Senior Faculty, Peter MacCallum ...

Melbourne, Australia

Comments (0)